News

Untire has become the first Cancer-Related Fatigue (CRF) app to be approved by the NHS, and is now available to download for free via the NHS apps library. See here. It aims to tackle CRF, one of the most common side effects of cancer and its treatment (Aug ’19).

A new US study sheds light on a signalling circuit in cells that drives therapy resistance in PCa. Targeting the components of this circuit suppresses advanced cancer development. See here.

A radioactive drug, which behaves like the substance used to kill Russian ex-spy Alexander Litvinenko, could be used to treat PCa patients. It targets tumours that have spread to the bones and has been approved by NICE. See here

A new risk assessment tool for GPs is set to revolutionise PCa diagnosis. See here. And NICE has agreed that abiraterone (Zytiga) is affordable after a lower price was agreed with the makers. See here.

Patients might be offered a more accurate prediction of their PCa risk with a novel method developed by Cambridge University researchers. See here

Urologists are committed to rolling out diagnostic use of the new MRI scans once their benefits are officially confirmed. The scans make it possible to rule out the need for a biopsy in many men who don’t have a clinically significant PCa. See here. Latest on this here.